Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.transci.2020.102790 http://scihub22266oqcxt.onion/10.1016/j.transci.2020.102790 32345485!7194745!32345485     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transfus+Apher+Sci 2020 ; 59 (3): 102790 Nephropedia Template TP {{tp|p=32345485|t=2020. Treatment for emerging viruses: Convalescent plasma and COVID-19 |pdf=|usr=}}{{32345485}} gab.com Text Treatment for emerging viruses: Convalescent plasma and COVID-19 JO: Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=32345485 #FOAvip Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. This report summarizes existing literature around convalescent plasma as a therapeutic option for COVID-19. It also includes recommendations for establishing a convalescent plasma program, enhancement considerations for convalescent plasma, and considerations around pathogen reduction treatment of convalescent plasma. Time is of the essence to set up protocols for collection, preparation, and administration of apheresis-collected convalescent plasma in response to the current pandemic. The immediate use of convalescent plasma provides prompt availability of a promising treatment while specific vaccines and treatments are evaluated and brought to scale. Further development of improved convalescent plasma, vaccines and other therapeutics depends on quick generation of additional data on pathogenesis and immune response. Additionally, given the lack of information around the natural history of this disease, PRT should be considered to add a layer of safety to protect recipients of convalescent plasma. Twit Text FOAVip Treatment for emerging viruses: Convalescent plasma and COVID-19 ????Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=32345485 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32345485 #FOAvip English Wikipedia <ref>{{Cite pmid|32345485}}</ref> Treatment for emerging viruses: Convalescent plasma and COVID-19 #MMPMID32345485 Brown BL; McCullough J Transfus Apher Sci 2020[Jun]; 59 (3): 102790 PMID32345485show ga Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. This report summarizes existing literature around convalescent plasma as a therapeutic option for COVID-19. It also includes recommendations for establishing a convalescent plasma program, enhancement considerations for convalescent plasma, and considerations around pathogen reduction treatment of convalescent plasma. Time is of the essence to set up protocols for collection, preparation, and administration of apheresis-collected convalescent plasma in response to the current pandemic. The immediate use of convalescent plasma provides prompt availability of a promising treatment while specific vaccines and treatments are evaluated and brought to scale. Further development of improved convalescent plasma, vaccines and other therapeutics depends on quick generation of additional data on pathogenesis and immune response. Additionally, given the lack of information around the natural history of this disease, PRT should be considered to add a layer of safety to protect recipients of convalescent plasma. |*Pandemics/prevention & control[MESH] |Antibodies, Neutralizing/blood/therapeutic use[MESH] |Antibodies, Viral/blood/therapeutic use[MESH] |Betacoronavirus/immunology[MESH] |Blood Safety[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Communicable Diseases, Emerging/*therapy/virology[MESH] |Convalescence[MESH] |Coronavirus Infections/blood/prevention & control/*therapy[MESH] |Donor Selection[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Meta-Analysis as Topic[MESH] |Plasmapheresis[MESH] |Pneumonia, Viral/blood/prevention & control/*therapy[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/therapy[MESH] |United States[MESH] |United States Food and Drug Administration[MESH]Treatment for emerging viruses: Convalescent plasma and COVID-19 (epmc).pdf DeepDyve Pubget Overpricing